Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895473 | 1.00 | PRMT5 (0.47) | PRMT5WDR77AAK1HCRTR1HCRTR2 | |
| SCHEMBL27118089 | 0.87 | PRMT5 (0.48) | PRMT5WDR77AAK1CA1CA9 | |
| SCHEMBL30874514 | 0.87 | CA1 (0.46) | CA1CA9CA2CA12CYP3A4 | |
| SCHEMBL21318698 | 0.87 | AAK1 (0.46) | PRMT5WDR77AAK1HCRTR1HCRTR2 | |
| SCHEMBL3319977 | 0.86 | PRMT5 (0.48) | PRMT5WDR77AAK1CA1CA9 | |
| SCHEMBL595545 | 0.85 | SIRT2 (0.47) | PRMT5WDR77AAK1SIRT2CYP3A4 | |
| SCHEMBL12567525 | 0.85 | AAK1 (0.48) | PRMT5WDR77AAK1CA1CA9 | |
| SCHEMBL30561474 | 0.85 | AAK1 (0.49) | PRMT5WDR77AAK1HCRTR1HCRTR2 | |
| SCHEMBL21030001 | 0.85 | AAK1 (0.49) | PRMT5WDR77AAK1HCRTR1HCRTR2 | |
| SCHEMBL3321460 | 0.85 | PRMT5 (0.46) | PRMT5WDR77AAK1CA1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478689-B2 | Anti-CD19 antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| EP-4539888-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250064962-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250064961-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250064963-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2025-02-27 | — | — | US | disclosed |
| US-12121589-B2 | Anti-CD19 antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2023245106-A9 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2006005918-A1 | 2, 4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1212327-B8 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064961-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD22, CD79B, CD47 | PRMT5 1306/4885WDR77 2654/4885AAK1 4449/4885 |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | PRMT5 17/4885WDR77 189/4885AAK1 2840/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | PRMT5 3008/4885WDR77 535/4885AAK1 1816/4885 |
| US-20250064963-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD22, CD79B, CD47 | PRMT5 1306/4885WDR77 2654/4885AAK1 4449/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | PRMT5 3008/4885WDR77 535/4885AAK1 1816/4885 |
| US-12121589-B2 | Anti-CD19 antibody drug conjugates | CD22, CD79B, CD47 | PRMT5 1306/4885WDR77 2654/4885AAK1 4449/4885 |
| US-12478689-B2 | Anti-CD19 antibody drug conjugates | CD22, CD79B, CD47 | PRMT5 1306/4885WDR77 2654/4885AAK1 4449/4885 |
| US-20250064962-A1 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | CD22, CD79B, CD47 | PRMT5 1306/4885WDR77 2654/4885AAK1 4449/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | PRMT5 1816/4885WDR77 3278/4885AAK1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.